<?xml version='1.0' encoding='UTF-8'?>
<DOC><DOCNO>WSJ910128-0031</DOCNO><DOCID>910128-0031.</DOCID><HL>   Business Brief -- Cel-Sci Corp.:   Virginia Biotechnology Firm   Ends Its Offering of Units</HL><DATE>01/28/91</DATE><SO>WALL STREET JOURNAL (J), NO PAGE CITATION</SO><CO>   CELI</CO><IN>MEDICAL AND BIOTECHNOLOGY (MTC)STOCK AND BOND REGISTRATIONS, PRICINGS (REG)STOCK MARKET, OFFERINGS (STK)</IN><LP>   Cel-Sci Corp. said it won't extend an offering of unitsbegun in November, and that it will refund about $500,000raised so far.   The biotechnology company, based in Alexandria, Va.,blamed the negative effects of the Mideast crisis for thepoor response. The company had been offering 4.86 millionunits -- each consisting of one common share and one warrant-- at $1 a unit.</LP><TEXT>   Maximilian de Clara, president, said the company is&quot;firmly committed to continue the present pace of its Randamp;Deffort,&quot; which includes the start-up of human trials with theHGP-30 AIDS vaccine in California and phase II clinicaltrials of a &quot;cocktail,&quot; or drug combination, cancer treatmentin Florida.   Once market conditions have stabilized, he said, thecompany &quot;may very well return to the financial markets foradditional funding.&quot;   A spokesman said that in the short term, the company willfocus on finding a &quot;strategic partner&quot; to help providefinancial and research support.</TEXT></DOC>